Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMK2
- Development stage
- Unknown
- Lead developer
- Omikron
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
OMK2 is an ophthalmic solution formulated as a combination of citicoline, vitamin B12 (cyanocobalamin), and hyaluronic acid. Developed by Omikron Italia, it is designed to provide neuroprotection and promote neuroregeneration in various ocular conditions, particularly those involving nerve damage. Citicoline acts as an essential precursor in the synthesis of phosphatidylcholine, a key component of neuronal cell membranes, thereby supporting the structural integrity and function of retinal ganglion cells. Vitamin B12 facilitates the healing and myelination of corneal nerve fibers, which is often compromised in diabetic patients or following surgical procedures like corneal cross-linking. Hyaluronic acid is included for its mucomimetic and lubricating properties, which help stabilize the tear film and protect the ocular surface. OMK2 is primarily utilized to mitigate the progression of diabetic retinopathy and to accelerate the recovery of corneal sensitivity and nerve morphology.
- Brand names
- OMK2OMK-2OMK 2
- Other names
- citicoline + vitamin B12 + hyaluronic acid ophthalmic solution
Beyond the preview
Go deeper on OMK2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMK2.